최신 재무제표(Form-10K)에 따르면, IRIDEX Corp의 총 자산은 $0이며, 순손실입니다.
IRIX의 주요 재무 비율은 무엇인가요?
IRIDEX Corp의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
IRIDEX Corp의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
IRIDEX Corp 주요 수익원은 Retina이며, 최신 수익 발표에서 수익은 30,280,000입니다. 지역별로는 United States이 IRIDEX Corp의 주요 시장이며, 수익은 23,210,000입니다.
IRIDEX Corp은 수익성이 있나요?
no, 최신 재무제표에 따르면 IRIDEX Corp의 순손실은 $0입니다.
IRIDEX Corp에 부채가 있나요?
no, IRIDEX Corp의 부채는 0입니다.
IRIDEX Corp의 발행 주식은 몇 주인가요?
IRIDEX Corp의 총 발행 주식은 0주입니다.
주요 통계
이전 종가
$1.03
시가
$1.03
일일 범위
$1.03 - $1.04
52주 범위
$0.8688 - $1.64
거래량
48.0K
평균 거래량
215.4K
배당수익률
--
EPS(TTM)
-0.26
시가총액
$18.1M
IRIX란 무엇인가요?
IRIDEX Corp. engages in developing, manufacturing, and marketing medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The company is headquartered in Mountain View, California and currently employs 93 full-time employees. The firm is developing, manufacturing, and marketing versatile laser-based medical systems, delivery devices and consumable instrumentation. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probe products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.